{"id":45743,"date":"2022-07-01T14:01:41","date_gmt":"2022-07-01T12:01:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/"},"modified":"2022-07-01T14:01:41","modified_gmt":"2022-07-01T12:01:41","slug":"olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/","title":{"rendered":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial"},"content":{"rendered":"
\n

SUWON, South Korea–(BUSINESS WIRE)–#AMD<\/a>—OliX Pharmaceuticals, Inc.<\/a> (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD).\n<\/p>\n

<\/a><\/p>\n

\nThe objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.\n<\/p>\n

\nAMD is the most common cause of blindness in the industrialized world, which affects more than 170 million people worldwide. AMD presents in 2 forms, geographic atrophy (GA) and neovascular AMD. Although treatments exist for many patients with neovascular AMD, a substantial number of patients remain insufficiently treated, and there is no FDA-approved drug for GA up to date. Therefore, the development of novel and safe AMD treatments presents as an important unmet medical need that OliX addresses with the development of OLX10212 for both indications.\n<\/p>\n

\nAccording to GlobalData, the global market for the treatment of AMD is expected to grow from USD 11.7 billion in 2022 to USD 18.7 billion in 2028.1)<\/sup>\n<\/p>\n

\n\u201cAlthough RNA interference (RNAi) technology has achieved great success in the treatment of liver diseases, its application to extra-hepatic organs is still in its infancy,\u201d said Dong Ki Lee, Ph.D., Founder and Chief Executive Officer of OliX Pharmaceuticals. \u201cWe at OliX are committed to bringing innovative and safe treatments to this severely ill patient population with advanced AMD. We are excited about this submission to the FDA because it presents as an important milestone not only for OliX but also for the entire field of RNAi therapeutics development as it is the first ophthalmic RNAi therapeutics entering the clinical stage since 2015.\u201d\n<\/p>\n

\nIn September 2020, OliX entered a licensing agreement with Th\u00e9a Open Innovation, a French company dedicated to ophthalmology, to transfer the worldwide rights (excluding Asia-Pacific) to eye disease treatment programs including OLX301A (program name of OLX10212).\n<\/p>\n

\n1) <\/sup>GlobalData, Pharma Intelligence Center, \u2018Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028<\/a>\u2019\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:<\/b>
Jiyoun Kim
\n
OliX Pharmaceuticals PR
\n
+82-2-3489-4801
\n
ccnc@olixpharma.com<\/a>
Learn more: https:\/\/www.olixpharma.com\/eng<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SUWON, South Korea–(BUSINESS WIRE)–#AMD—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this Phase … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45743","6":"format-standard","7":"category-industry"},"yoast_head":"\nOliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SUWON, South Korea–(BUSINESS WIRE)–#AMD—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this Phase ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-01T12:01:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220701005097\/en\/1396983\/21\/LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial\",\"datePublished\":\"2022-07-01T12:01:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/\"},\"wordCount\":379,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005097\\\/en\\\/1396983\\\/21\\\/LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/\",\"name\":\"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005097\\\/en\\\/1396983\\\/21\\\/LOGO.jpg\",\"datePublished\":\"2022-07-01T12:01:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005097\\\/en\\\/1396983\\\/21\\\/LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005097\\\/en\\\/1396983\\\/21\\\/LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial - Pharma Trend","og_description":"SUWON, South Korea–(BUSINESS WIRE)–#AMD—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this Phase ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-01T12:01:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220701005097\/en\/1396983\/21\/LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial","datePublished":"2022-07-01T12:01:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/"},"wordCount":379,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220701005097\/en\/1396983\/21\/LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/","url":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/","name":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220701005097\/en\/1396983\/21\/LOGO.jpg","datePublished":"2022-07-01T12:01:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220701005097\/en\/1396983\/21\/LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220701005097\/en\/1396983\/21\/LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/olix-pharmaceuticals-announces-ind-submission-to-u-s-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45743"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45743\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}